Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against enGene Therapeutics Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of enGene Therapeutics Inc. (“enGene” or “the Company”) (NASDAQ: ENGN). Investors who purchased enGene securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether enGene has violated federal securities laws.
enGene Investigation Details
On May 7, 2026, enGene revealed updated interim results from its ongoing Phase 2 LEGEND trial of its bladder cancer drug candidate, detalimogene voraplasmid. The Company admitted that “durability outcomes to date are not what we hoped.” Following this news, enGene’s stock price dropped by nearly 80.6% on the same day.
What’s Next for enGene Investors?
If you are aware of any facts relating to this investigation or purchased enGene securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
ENGN — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”